COMPANY

Verismo Therapeutics

HQ: Philadelphia, PA source · verismotherapeutics.com ↗ · Mid-Atlantic

Keywords: cell therapy oncology solid tumors blood cancers Ovarian Cancer Cholangiocarcinoma Recurrent Malignant Mesothelioma B Cell Lymphoma Adult NHL Mantle Cell Lymphoma Relapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Aggressive B-Cell Non-Hodgkin Lymphoma Indolent B-Cell Non-Hodgkin Lymphoma Follicular Lymphoma Marginal Zone Lymphoma DLBCL - Diffuse Large B Cell Lymphoma HGBL With MYC and BCL2 and/or BCL6 Rearrangements High-grade B-cell Lymphoma Diffuse Large B Cell Lymphoma Large B-cell Lymphoma T-Cell/Histiocyte Rich Lymphoma Non-hodgkin Lymphoma,B Cell Primary Mediastinal Large B-cell Lymphoma Nos Epstein-Barr Virus Positive DLBCL Follicular Lymphoma Grade 3B DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation Not Otherwise Specified High Grade B-Cell Lymphoma Follicular Lymphoma Grade 3 Marginal Zone Splenic Lymphoma DLBCL Waldenstrom Macroglobulinemia Waldenstrom Macroglobulinaemia SynKIR-310

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $28M (Form D filed May 20, 2026). SEC Form D 0001855431-26-000003 (May 20, 2026)
Evidence (1 event)
- May 20, 2026 · SEC Form D 0001855431-26-000003
  Name of Issuer: Verismo Therapeutics, Inc.; CIK: 1855431; Address: Philadelphia, PA; Submission type: D; Filing date: 2026-05-20; Industry Group: Other Health Care; Date of First Sale: 2026-04-21; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 28000000; Total Amount Sold: 28000000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jan 27, 2025 Trial start —: A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product source ↗
Nov 1, 2024 Trial start Phase 1: SynKIR-310 for Relapsed/Refractory B-NHL source ↗
Nov 15, 2023 Trial start —: Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies source ↗
Mar 30, 2023 Trial start Phase 1: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 1 · SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma · NCT05568680
2028-09 (ESTIMATED) · Phase 1 · SynKIR-310 for Relapsed/Refractory B-NHL · NCT06544265
2042-02 (ESTIMATED) · · A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product · NCT06701201

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06701201	A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product	Not listed	Enrolling by invitation	Jan 27, 2025	2042-02 (estimated)
NCT05568680	SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma	Phase 1	Recruiting	Mar 30, 2023	2027-12 (estimated)
NCT06544265	SynKIR-310 for Relapsed/Refractory B-NHL	Phase 1	Recruiting	Nov 1, 2024	2028-09 (estimated)
NCT06377202	Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies	Not listed	Withdrawn	Nov 15, 2023	Dec 15, 2038 (estimated)